A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin

Recruiting now · Phase 3 · Has a placebo group

Conditions studied: Overweight, Obesity

In brief

The main purpose of this study is to evaluate the efficacy and safety of eloralintide compared with placebo in participants with persistent obesity or overweight, with or without type 2 diabetes, and on stable incretin background therapy. Participation in the study will last about 80 weeks.

Key facts

Study ID

NCT07392190

Run by

Eli Lilly and Company

People needed

900

Starts

2026-02-10

Expected to finish

2028-07-01

Last updated by the study team

2026-08-06

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Are on stable incretin therapy at screening
• With persistent obesity or overweight defined as:
• ≥30 kg/m2 OR
• ≥27 kg/m2 with at least one existing obesity related complication at screening:
• hypertension
• dyslipidemia
• obstructive sleep apnea
• cardiovascular disease (for example, ischemic cardiovascular disease, New York Heart Association Functional Class I-III heart failure), or
• type 2 diabetes
• Have a stable body weight (<5% body weight change) at screening

You may not qualify if…

• Have a prior or planned surgical treatment for obesity (liposuction, cryolipolysis, or abdominoplasty allowed if performed >1 year before screening)
• Have a prior or planned endoscopic procedure and/or device-based therapy for obesity (prior device-based therapy acceptable if device removal was more than 6 months prior to screening)
• Have type 1 diabetes
• Have taken any of the following antihyperglycemic medications within 90 days before screening:
• dipeptidyl peptidase-4 (DPP-4) inhibitors
• amylin analogs
• insulin
• Have had within 90 days prior to screening:
• heart attack
• stroke
• coronary artery revascularization
• unstable angina, or
• hospitalization due to congestive heart failure
• Have a history or diagnosis of New York Heart Association Functional Classification Class IV congestive heart failure

Where it is running

• RIO Clinical Trials - Phoenix — Phoenix, Arizona, United States (enrolling)
• Family First Medical Center — Idaho Falls, Idaho, United States (enrolling)
• Novak Clinical Research - Tucson - North La Cholla Boulevard — Tucson, Arizona, United States (enrolling)
• Irvine Clinical Research — Irvine, California, United States (enrolling)
• Birmingham Clinical Research — Birmingham, Alabama, United States (enrolling)
• Headlands Research - Scottsdale — Scottsdale, Arizona, United States (enrolling)
• Peninsula Research Associates — Rolling Hills Estates, California, United States (enrolling)
• Care Access - Sacramento — Sacramento, California, United States (enrolling)
• Artemis Institute for Clinical Research — San Diego, California, United States (enrolling)
• Southern California Clinical Research — Santa Ana, California, United States (enrolling)
• Scripps Whittier Diabetes Institute — La Jolla, California, United States (enrolling)
• New England Research Associates, LLC — Bridgeport, Connecticut, United States (enrolling)
• Yale University School of Medicine — New Haven, Connecticut, United States (enrolling)
• Chase Medical Research, LLC — Waterbury, Connecticut, United States (enrolling)
• JEM Research Institute — Atlantis, Florida, United States (enrolling)
• AMR Clinical — Doral, Florida, United States (enrolling)
• Northeast Research Institute (NERI) — Fleming Island, Florida, United States (enrolling)
• Jacksonville Center for Clinical Research — Jacksonville, Florida, United States (enrolling)
• New Horizon Research Center — Miami, Florida, United States (enrolling)
• St Johns Center for Clinical Research — Saint Augustine, Florida, United States (enrolling)
• Metabolic Research Institute, Inc. — West Palm Beach, Florida, United States (enrolling)
• Teak Research Consults - Dunwoody — Dunwoody, Georgia, United States (enrolling)
• Center for Advanced Research & Education — Gainesville, Georgia, United States (enrolling)
• University Clinical Investigators, Inc. — Tustin, California, United States (enrolling)
• Great Lakes Clinical Trials - Ravenswood — Chicago, Illinois, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.